



PILA PHARMA AB

Medeon Science Park
Per Albin Hanssons väg 41
205 12 Malmö, Sweden

pilapharma.com

For immediate release

Malmö, Sweden, 6th December 2017

PILA PHARMA passes the start-up phase, prepares for efficacy trials and increases focus on 'Effective and Affordable Medicine' by electing the health economist Ulrikka Klarskov Kjær to the Board of Directors

PILA PHARMA, founded in 2014, now counts +10 core members and has thus passed the "start-up" phase. "We are about to move out of the Medeon Incubator in Malmö and have also established a Danish affiliate to handle the R&D activities in Denmark", says Dorte X. Gram, CEO of PILA PHARMA.

Given the fact that PILA PHARMA has established itself as a young, but serious player in the diabetes field and that the company has been able to recruit an extremely competent staff to develop the company, Per Antonsson from Almi Invest has decided to step down from the Board of Directors in order to focus on new start-up projects in Almi's portfolio.

Per Antonsson says: "I was one of the very first to see the potential in PILA PHARMA and we were the first external investor to join almost 3 years ago. I have been delighted to be actively involved in the company's lift-off as well as being a member of the Board of Directors. The company has now grown to a size and maturity where I consider it to be stable enough for me to scale down my day-to-day engagement. I would like to thank Dorte for her commitment and strong will to succeed, and, as the second-largest investor in the company, I will follow the company from the outside with continued interest."

Dorte X. Gram, CEO of PILA PHARMA states: "We have been privileged to have had access to Per's experience and network. Per has played a crucial role in the company's start-up phase shaping the company to allow for future growth. We consider his wish to step down from the Board, to be a statement of his positive thoughts on PILA PHARMA."

Erik Nerpin, Chairman of the Board, continues: "Per has been a very engaged member of the Board, and we will miss his contributions to the strategic decisions we make. In the search to find a suitable replacement to Per, it has been important to add new skills, and we have analysed the forthcoming challenges and opportunities for PILA PHARMA. The Board of Directors has identified positioning of XEN-D0501 as a better and cheaper drug-choice as very important. We therefore look forward to welcoming Ulrikka Klarskov Kjær and her unique competences within international health economics to the Board of Directors."

Ulrikka Klarskov Kjær supplements: "The world, and in particular developing regions like Africa, need access to effective and affordable treatments of diabetes to tackle the healthrelated and economic consequences of the disease. Therefore, I'm delighted to join PILA PHARMA to help elucidating the potential health economic benefits of XEN-D0501 in treating diabetes and potentially obesity in the future.

Ulrikka holds a double degree with an MSc in Health Economics as well as an MA in African Studies and has worked on multiple international projects. In addition, she has extensive specialist and managerial experience from Danish appointments at Novo Nordisk, Rambøll and Ledøje-Smørum Municipality, the latter as Director of Health and Social Affairs.

For further information, please visit: [PILA PHARMA Board of Directors](#).



Notes to Editors:

Contact:

PILA PHARMA

Dorte X. Gram, CEO
M: +46 (0)73 903 6969
E: dxg@pilapharma.com

About PILA PHARMA

PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden that is developing XEN-D0501, a TRPV1 antagonist, as an effective and affordable treatment of diabetes and associated obesity.

For further information, please visit: pilapharma.com

About diabetes

Diabetes is a worldwide pandemic with a staggering prevalence of more than 425 m diabetics corresponding to approximately 8-10% of the population.

The disease can lead to cardiovascular disease resulting in reduction of quality of life for the patient, increased risk of death and high health care expenses. Approximately 90 % of all diabetics suffer from type 2 diabetes, whilst approximately 10% suffers from type 1 diabetes.